I'm LongbridgeAI, I can summarize articles.BWS Financial maintains a Sell rating on Twist Bioscience with a $45 price target, implying a 71.1% downside from the September 17 close of $155.56. The analyst cites weak financial performance, insufficient revenue growth, and increasing market competition in the synthetic biology sector as key factors impacting profitability.
BWS Financial maintained their Sell rating on Twist Bioscience's stock with a price target of $45.00.
The price target implies a downside of 71.1% from the Sep 17 close of $155.56.
Key takeaways from the analyst note
Weak Financial Performance: Twist Bioscience has been struggling to generate sufficient revenue growth, leading analysts to question the sustainability of its business model and overall financial health.
Market Competition and Pricing Pressure: The synthetic biology space is becoming increasingly competitive, with numerous players entering the market, which could lead to pricing pressure and further impact Twist Bioscience's profitability.
Explore more price target data and ratings for Twist Bioscience on the .